1. Home
  2. CHCO vs GLPG Comparison

CHCO vs GLPG Comparison

Compare CHCO & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo City Holding Company

CHCO

City Holding Company

HOLD

Current Price

$125.76

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$27.73

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHCO
GLPG
Founded
1957
1999
Country
United States
Belgium
Employees
N/A
452
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
CHCO
GLPG
Price
$125.76
$27.73
Analyst Decision
Hold
Buy
Analyst Count
2
2
Target Price
$132.50
$36.50
AVG Volume (30 Days)
71.4K
171.4K
Earning Date
04-23-2026
05-06-2026
Dividend Yield
2.87%
N/A
EPS Growth
13.18
N/A
EPS
2.20
N/A
Revenue
N/A
N/A
Revenue This Year
$5.16
N/A
Revenue Next Year
$3.12
N/A
P/E Ratio
$56.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$113.21
$26.62
52 Week High
$133.59
$37.78

Technical Indicators

Market Signals
Indicator
CHCO
GLPG
Relative Strength Index (RSI) 58.13 36.53
Support Level $119.61 N/A
Resistance Level $128.20 $34.04
Average True Range (ATR) 2.09 0.56
MACD 0.19 0.08
Stochastic Oscillator 87.51 25.33

Price Performance

Historical Comparison
CHCO
GLPG

About CHCO City Holding Company

City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: